Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial

Background: GLP-1 receptor agonists (GLP-1 RAs) have been shown to improve glycemic control and insulin sensitivity and reduce body weight in obese patients with type 2 diabetes mellitus (T2D). This trial sought to evaluate the therapeutic effect of oral and subcutaneous semaglutide in NAFLD and its...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Ahmed I. Gad, Nevin F. Ibrahim, Noura Almadani, Rasha Mahfouz, Hanaa A. Nofal, Dina S. El-Rafey, Hossam Tharwat Ali, Amr T. EL-Hawary, Ayman M. E. M. Sadek
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2024-08-01
Rangatū:	Diseases
Ngā marau:	semaglutide nonalcoholic fatty liver disease obesity type 2 diabetes mellitus GLP-1 clinical trial
Urunga tuihono:	https://www.mdpi.com/2079-9721/12/8/186
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!